Printer Friendly

FDA warns on fracture risks with PPIs.

The Food and Drug Administration issued a warning to physicians and consumers that proton pump inhibitors may increase the risk of hip, wrist, and spine fractures.

The agency said that it is changing the labeling for prescription and over-the-counter versions of proton pump inhibitors (PPIs) to reflect new safety information that is the result of a review of seven epidemiologic studies. Most of the observed risk was in people older than age 50 years and those who took high doses or used the drugs for more than a year. Prescription PPIs include esomeprazole (Nexium), dexlansoprazole (Dexilant), omeprazole (Prilosec, Zegerid), lansoprazole (Prevacid), pantoprazole (Protonix), and rabeprazole (Aciphex). There are OTC versions of Prilosec, Zegerid, and Prevacid.

"Because these products are used by a great number of people, it's important for the public to be aware of this possible increased risk and, when prescribing proton pump inhibitors, health care professionals should consider whether a lower dose or shorter duration of therapy would adequately treat the patient's condition," said Dr. Joyce Korvick, deputy director for safety in FDA's Division of Gastroenterology Products, in a statement.

The FDA did not have access to the raw data in the studies; it merely reviewed what was published. But, said the FDA, it accepted the results because the studies appear to be well designed. Even so, those studies had limitations, and there is still no understanding of why PPIs might lead to fractures.

The full agency communication is located at
COPYRIGHT 2010 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:GYNECOLOGY
Author:Ault, Alicia
Publication:OB GYN News
Date:Jul 1, 2010
Previous Article:Ovarian Ca screen could detect early disease.
Next Article:Improving survival in cervical cancer patients.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters